Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
In the Medical segment, sales of € 82.8 million were around € 17.6 million or 27% higher than in the previous year. The main growth driver continues to be business with pharmaceutical radioisotopes, while sales of laboratory equipment and in the plant engineering division also continued to increase.
At € 101.0 million, the Isotope Products segment generated slightly higher external sales of € 0.5 million than in the first nine months of 2022. The segment’s sales thus remained stable.
The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of around € 230 million and net income of around € 25 million.
The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz323e.pdf
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
